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Abstract
Background: It is suggested that interleukin (IL)-13 and transforming growth factor (TGF)-beta play a role in the
pulmonary vascular changes found in animal models of schistosomiasis. The aim of this study was to assess and
compare the serum levels of total TGF-beta and IL-13 of patients with schistosomiasis with pulmonary arterial
hypertension (PAH) and patients with schistosomiasis without PAH.
Methods: 34 patients from the schistosomiasis outpatient clinic of the Hospital das Clinicas, Recife, Pernambuco,
Brazil, without PAH assessed by echocardiography and 34 patients from the Reference Centre of Pulmonary
Hypertension of Pronto Socorro Cardiológico de Pernambuco, Recife, Brazil with PAH, confirmed by right heart
catheterization, were enrolled on the study. Both groups presented with schistosomal periportal fibrosis after
abdominal ultrasound. Serum levels of TGF-beta1 and IL-13 were determined by ELISA. Student t test to independent
samples, Mann-Whitney test to nonparametric variables, Pearson correlation test for correlation analyses and Fisher
Chi-squared test to compare categorical analyses were used.
Results: The median value of TGF-beta1 was significantly higher in patients with PAH (22496.9 pg/ml, interquartile
range [IR] 15936.7 – 32087.8) than in patients without PAH (13629.9 pg/ml, IR: 10192.2- 22193.8) (p = 0.006). There was no
difference in the median value of IL-13 in the group with Sch-PAH compared to patients without Sch-PAH (p > 0.05).
Conclusion: Our results suggest that TGF-beta possibly plays a role in the pathogenesis of schistosomiasis-associated PAH.
Keywords: Schistosomiasis, Pulmonary hypertension, Transforming growth factor-beta, Interleukin 13
Background
Pulmonary arterial hypertension (PAH) is defined
hemodynamically as an increase in mean pulmonary
arterial pressure (PAP) ≥ 25 mmHg at rest and pulmon-
ary artery occlusion pressure ≤ 15 mmHg, characterized
by the remodelling of the pulmonary vasculature that
causes progressive dyspnea and can lead to right-sided
heart failure and premature death [1]. It may be caused by
several conditions including idiopathic PAH, connective
tissue disease, HIV infection, schistosomiasis and others
[2]. Around 240 million people are infected with some
species of Schistosoma throughout the world, mainly S.
japonicum, S. haematobium and S. mansoni, the latter be-
ing responsible for almost all cases of schistosomiasis-
associated pulmonary arterial hypertension (Sch-PAH)
[3-5]. Sch-PAH represents 30.8% of all causes of PAH in
endemic areas of S. mansoni, and is considered the leading
cause of PAH in these areas [6]. Hospital-based studies in
Brazil, where S. mansoni is endemic, have reported pul-
monary hypertension in approximately 10% of patients with
schistosomal periportal fibrosis, using echocardiographic
assessment [7,8], but only 4.7% of patients with the hepa-
tosplenic form of the disease presented PAH confirmed by
right heart catheterization (RHC) [8].
The main lesion caused by S. mansoni is due to an
intense immune reaction against the parasite eggs trapped
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in small branches of the intrahepatic portal vein, result-
ing in chronic granulomas that stimulate the development
of fibrosis in the portal spaces [5,9]. Granuloma formation
is a predominantly T helper (Th) cell-dependent process,
with an early Th1 proinflammatory response (IL-1, IL-12,
interferon gamma, transforming growth factor beta [TGF –
beta] and tumour necrosis factor-alfa), in which a switch
occurs following egg production to a predominant Th2
immune response (IL-4, IL-5, IL-10 and IL-13) that plays a
central role in the modulation of granuloma immune
response [10-14].
Depending on the intensity of the fibrotic reaction
around the portal veins, almost 5-10% of chronically
infected individuals will suffer blockage of the hepatic
blood flow and secondary portal hypertension [15]. The
downstream effect is when the naturally occurring portal-
systemic collateral vessels open to decompress the portal
system [16,17], which allows embolization of eggs to the
lungs. A secondary granulomatous reaction is triggered in
the pulmonary vascular bed and gives rise to obliterative
arteritis and vascular remodeling, which in some individ-
uals results in PAH [18]. This is the main mechanism
which is generally believed to be related to the develop-
ment of Sch-PAH. However, a recent study failed to dem-
onstrate a significant amount of parasite-derived antigens
within the lungs of individuals who had died of Sch-PAH
[19], but the histologic and vascular changes encountered
were similar to those described in idiopathic PAH [20].
This suggests that embolization of eggs to the lungs is not
the sole mechanism responsible for establishing PAH [19].
It is possible that genetic determinants are involved in
the development of the disease. Around 80% of patients
with familial PAH and 25% with idiopathic PAH present
mutations in the gene encoding the bone morphogenetic
protein receptor type II (BMPR-II), a member of the
TGF-beta superfamily [21]. This leads to a change in the
signaling of the TGF-beta superfamily. There is strong
evidence to suggest that the TGF-beta system, by stimu-
lating the proliferation of pulmonary arterioles, induces
vasculogenesis [22,23].
Studies have suggested that IL-13, an important medi-
ator of granulomatous and vascular responses in the schis-
tosomotic infection, acts in conjunction with the TGF-
beta system, and its increased activity has been found in
animals with Sch-PAH [24-26]. Moreover, TGF-beta
signaling is higher in mice exposed to Schistosoma and pa-
tients who have died of Sch-PAH than in control samples.
Besides this, the increase in TGF-beta after Schistosoma
exposure is dependent on IL-4 and IL-13 in the animal
model [27].
The aim of this study was to assess the serum con-
centrations of TGF-beta1 and IL-13 in patients with
Sch-PAH and compare them with patients with schisto-
somiasis without PAH.
Methods
Study population, participants, ethical approval and
exclusion criteria
This was a descriptive study with comparative groups. Pa-
tients with schistosomal periportal fibrosis and PAH con-
firmed by RHC (mean PAP ≥ 25 mmHg and pulmonary
capillary wedge pressure ≤ 15 mmHg) were recruited from
the pulmonary hypertension referral center at the Pronto
Socorro Cardiológico de Pernambuco, Recife, Brazil. The
comparative group consisted of patients with schistosomal
periportal fibrosis without pulmonary hypertension asse
ssed by Transthoracic Doppler echocardiography and
matched by sex and age, from the schistosomiasis out-
patient clinic at the Hospital das Clínicas, Universidade
Federal de Pernambuco, Recife, Brazil.
Patients were selected from July 2010 to December
2012, and the study was approved by the Research Ethics
Committee of the Universidade Federal de Pernambuco
(registration number at SISNEP Fr-326154/CAAE-0096.
0.172.000-10/REGISTRATION CEP/CCS/UFPE 099/10).
All patients received an explanation concerning the scope
of the study, and signed an Informed Consent Form. This
study was conducted according to the Helsinki Declaration.
Exclusion criteria were: age ≤ 18 years of age; a history
of alcohol abuse (alcohol intake in excess of 210 g/week
for males and 140 g/week for females over the previous
5 years) [28]; evidence of non-schistosomal liver disease
by ultrasound or clinical examination; hepatitis B or C
viruses and/or HIV infection; evidence of congenital heart
diseases (i.e. atrial septal defects); left-sided heart disease;
moderate or severe lung disease (forced vital capacity
[FVC] and/or forced expired volume in one second [FEV1]
and/or FEV1/VFC ≤ 60% of predicted); and/or diagnosis of
connective tissue disease.
Diagnosis of PAH and schistosomiasis
All patients were previously submitted to abdominal ultra-
sound in order to define the presence of schistosomal
periportal fibrosis, which was classified according to
Niamey criteria [29] as: C-peripheral, D-central, E-
advanced and F-very advanced (Siemens Acuson X150®
with3,5 mHz convex transducers). The groups with and
without PAH were compared in relation to each pattern
of fibrosis.
The included patients with periportal fibrosis presented
with the hepatointestinal (spleen longitudinal diameter <
120 mm) and hepatosplenic forms of schistosomiasis
(spleen longitudinal diameter of ≥120 mm). The diameters
of the porta and splenic veins were considered enlarged if
they exceeded 12 mm and 9 mm, respectively. The pres-
ence of collateral vessels was also reported.
A Doppler echocardiography was performed on the
comparative group to exclude PAH, using standard proce-
dures [30] (Philips EnVisor C® system with 2.5 and 3.5
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mHz mHz transducers). The following parameters were
considered in order to exclude PAH: tricuspid regurgita-
tion velocity ≤ 2.8 m/s, pulmonary artery systolic pres-
sure ≤ 36 mmHg and no additional echocardiographic
variables suggestive of pulmonary hypertension (increased
velocity of pulmonary valve regurgitation, short acceler-
ation time of right ventricular ejection into pulmonary
artery, increased dimensions of right heart chambers,
abnormal shapes and function of the interventricular
septum, increased right ventricular wall thickness, and
dilated pulmonary artery) [1].
The functional classification of patients with PAH was
determined according to the modified World Health
Organization classification from the New York Heart
Association [31]. Those patients with PAH were previ-
ously submitted to RHC. Access to the venous and fem-
oral arteries was obtained using the Seldinger technique.
Catheterization was performed in the right and left cham-
bers of the aorta, and manometry was conducted on the
left ventricle, pulmonary artery, right ventricle and right
atrium using a 06-French pigtail catheter and a 07-French
wedge catheter for the occluded capillary wedge pressure.
The output and resistance calculations were performed
using the Fick method [32].
Sample collection and assay
Venous blood samples were collected under aseptic con-
ditions, using vacuum tubes (BD, Becton Dickinson, UK)
without anticoagulants. Samples were centrifuged for 5 min
at 2000 × g and the serum was stored in 0.5 ml aliquots at
−80°C until assayed. The levels of TGF-beta1 and IL-13
were assessed using a sandwich enzyme-linked immuno-
sorbent assay (ELISA) (R&D Systems, Inc, Minneapolis,
MN). To activate latent TGF-beta1 to the immunoreactive
form, 1 N HCl was used for acid activation and 1.2 N
NaOH/0.5 M HEPES for neutralization. After activation,
the samples (serum) were diluted and the concentration
was measured according to the ELISA kit. The presence of
cytokines was revealed and the results were expressed as
pg/ml in accordance to standard curves. The assay sensitiv-
ity to TGF-beta1 was 15.4 pg/ml and to IL-13 57.4 pg/ml.
Statistical analysis
The data was incorporated into the database Epi Info 3.02
and analysed using STATA. Results were presented as me-
dian and percentiles (interquartile range). Comparisons
for quantitative variables were conducted using the Stu-
dent t-test for independent samples, the Mann–Whitney
test for nonparametric variables, and the Pearson correl-
ation test for correlation analyses. The Fisher Chi-squared
test was used to compare the categorical variables: sex,
clinical form of schistosomiasis and periportal fibrosis
pattern between the patients with and without PAH. A
p value <0.05 was considered as statistically significant.
Results
Thirty four patients with Sch-PAH and periportal fibrosis
and 34 patients with periportal fibrosis without PAH diag-
nosed by Doppler echocardiography and matched by sex
and age, concluded the study. One female with FEV1/
VFC ≤ 60% and one male who was HbsAg antigen positive
were excluded from the control group. Two women with
PAH were also excluded: one presented with a previous
diagnosis of cutaneous scleroderma and the other with
atrial septal defect. The clinical and hemodynamic vari-
ables of the patients with Sch- PAH are shown in Table 1.
Twenty seven (79.4%) patients were taking medication for
PAH at the time of inclusion: 25 were on phosphodiester-
ase inhibitors, one on bosentan and one on calcium chan-
nel blockers (Table 1). There was no difference between
groups regarding age, sex, the periportal fibrosis pattern
and portal vein diameter (Table 2). The longitudinal diam-
eter of the spleen was wider in the control group, without
PAH. All patients in the control group and 30 patients
with Sch-PAH presented the hepatosplenic form of schis-
tosomiasis and only four patients in the Sch-PAH group
presented the hepatointestinal form of the disease
(Table 2).
Median serum levels of immunoreactive TGF-1 beta were
significantly higher in patients with Sch-PAH compared to
patients without PAH (22496.9 [IR: 15936.7 – 32087.8]
pg/ml versus 13629.9 [IR: 10192.2 – 22193.8] pg/ml) (p =
0.006). There was no difference in the median value of IL-
13 in the group with Sch-PAH (152.3 [IR: 103.7 - 177.8])
pg/ml, compared to patients without PAH (131.8 [IR:
100.2 - 162.5]) pg/ml (p = 0.177) (Table 2).
Discussion
The present study has demonstrated significantly higher
serum levels of immunoreactive TGF-beta1 in patients
with Sch-PAH compared with patients with schistosomia-
sis without PAH. TGF-beta 1 is one isoform of TGF-beta
that causes enhanced cell proliferation in smooth muscle
Table 1 Clinical and hemodynamic characteristics of
patients with schistosomiasis-associated pulmonary
arterial hypertension
Variables Patients Characteristics
Functional class I/II/III/IV/N 34 9/10/7/8
Drugs to PAH/N (%) 34 27 (79.4%)
Mean PAP mmHg median (P25; P75) 34 55.5 (46; 62.7)
RAP mmHg median (P25; P75) 29 13 (9; 16)
LVEDP mmHg median (P25; P75) 32 14 (11.7; 15)
CI l/min/m2 median (P25; P75) 25 2.68 (1.97; 3.67)
PVR Dyn/sec/cm median (P25; P75) 30 989.5 (644.5; 1417.5)
Recife, 2012.
CI – cardiac index; LVEDP-left ventricular end-diastolic blood pressure;
PAP- pulmonary artery pressure; N - sample size; PAH – pulmonary arterial
hypertension; PVR- pulmonary vascular resistance; RAP- right arterial pressure.
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cells in the pulmonary arteries of patients with idiopathic
PAH and has a growth-inhibitory effect on normal cells
[33]. A previous study has already demonstrated elevated
levels of TGF-beta1 and other growth factors in serum
samples of 46 patients with PAH with other diverse etiolo-
gies compared to 20 controls, and suggested that these sub-
stances may contribute to vascular remodeling in PAH [34].
The link between TGF-beta and the pathogenesis of
Sch-PAH has been studied in animal models. The
altered signaling of the TGF-beta system was demon-
strated in experimental mouse models infected with
Schistosoma and in lung specimens obtained from aut-
opsies of individuals who had died of Sch-PAH through
increased Smad2/3 activity found in the affected vessels
[19]. Smads are proteins that can be phosphorylated
after the attachment of TGF-beta in cell receptors, and
which are able to move to the nucleus of the cells, alter-
ing essential functions [22]. The TGF-beta system is a
probable pathway to direct the proliferation of pulmon-
ary arterioles in PAH, leading to vasculogenesis, as well
as intimal hyperplasia and growth of the media layer
[21-23]. It is believed that in the case of PAH linked with
BMPR-II mutation, the main mechanism is the imbal-
ance secondary to the loss of BMPR-II function, associ-
ated with the increased activation of the TGF-beta
superfamily of receptors [22].
Studies using the inhibition of TGF-beta in experi-
mental models of PAH have confirmed the role of this
growth factor in the pathogenesis of PAH and have indi-
cated its possible use in the treatment of this disease
[35-37]. PAH was induced in rats by monocrotaline
injection, and the later treatment with an antibody
against TGF-beta-ligand decreased the pulmonary artery
systolic pressure and right ventricular hypertrophy,
increased exercise capacity and reduced pulmonary vascu-
lar remodeling as evidenced by decreased vessel-wall
thickness and number of pre-capillary arterioles. This
effect occurred with bosentan, the endothelin receptor
blocker. TGF-beta regulates endothelin-1 synthesis, which
is a possible mediator of TGF-beta actions [38]. More
recently, Graham et al. [27] demonstrated that a mouse
model of Sch-PAH submitted to pharmacological block-
age of the TGF-beta ligand and receptor and that mice
lacking Smad3 were significantly protected from pulmon-
ary vascular remodeling and PAH. This blockage also led
to a decrease in IL-4 and IL-13 concentrations [27]. A
significant increase was encountered in the levels of TGF-
beta1 mRNA as measured by RNA sequencing in S.
mansoni-exposed mice compared with unexposed mice,
and there was no change in the TGF-beta2 and TGF-
beta3 expressions with S. mansoni exposure. A more
extensive expression was observed of phosphor-Smad2/3
in the pulmonary vascular intimal, medial, and adventitial
regions in experimental Sch-PH lungs compared with
control mice. These authors also demonstrated an
increased expression of Smad2/3 within the pulmonary
vascular media compartment in subjects who had died of
Sch-PAH compared with control human lungs [27].
Accordingly, the present study also measured the TGF-
beta1 isoform, and our results were similar, in that they
supported a role played by this growth factor in the patho-
genesis of Sch-PAH.
Table 2 Comparison of patient characteristics according to the condition of schistosomiasis-associated pulmonary
arterial hypertension
Groups General With Sch-PAH Without Sch-PAH p-value
Samples 68 34 34 -
Age (mean ± sd) 49.3 ± 12.9 49.8 ± 13.2 49.8 ± 12.8 0.759a
Sex: Male 24 (35.3%) 11 (32.3%) 13 (38.2%) 0.612
Clinical form
Hepatosplenic 64 (94.1%) 30 (88.2%) 34 (100%) 0.039c
Hepatointestinal 04 (5.9%) 04 (17.8%) 00 (−)
Periportal fibrosis
Dx 24 (35.3%) 13 (38.2%) 11 (32.3%)
E 37 (54.4%) 18 (52.9%) 19 (55.9%) 0.674c
F 07 (10.3%) 03 (8.9%) 04 (11.8%) 0.685
TGF-β1 pg/ml (median – P25; P75) 19442.2 (11070.4; 30097.2) 22496.9 (15936.7; 32087.8) 13629.9 (10192.2; 22193.8) 0.006b
IL-13 pg/ml (median – P25; P75) 152.3 (100.2; 165.0) 152.3 (103.7; 177.8) 131.8 (100.2; 162.5) 0.177
b
Portal vein diameter cm 1.15 ± 0.33 1.09 ± 0.37 1.23 ± 0.25 0.085a
Spleen diameter cm 14.5 ± 3.3 12.7 ± 2.17 16.4 ± 3.3 0.000a
Recife, 2012.
aStudent’s t-test; bMann–Whitney nonparametric test; c Fisher X2 test; xReference value, D- central fibrosis; E- advanced fibrosis; F- very advanced fibrosis;
TGF-β1 – transforming growth factor-beta 1; IL-13- interleukin-13.
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There was no difference in the median value of IL-13 in
the group with Sch-PAH, compared to patients without
PAH, contrary to that observed in animal models. Crosby
et al. [26], using mice experimentally infected with Schis-
tosoma, discovered that the grade of pulmonary vascular
remodeling correlated with the egg burden in the lungs
and with plasma Th1 and Th2 cytokines. Furthermore, IL-
13 stimulated the migration of mouse pulmonary artery
smooth muscle cells in transwell assays. There was a peak
of cytokines IL-10, IL-13, IL-6 and IL-4, 17 weeks after
infection [26]. In this animal model, transcutaneous infec-
tion of the animals with cercariae before the intravenousin-
jection of Schistosoma eggs some weeks later was required
for PAH development, suggesting that a potent inflamma-
tory response in the lungs due to prior sensitization is
necessary to elicit PAH, more than the mere embolization
of eggs in the lungs [25,26].
IL-13 signaling is mediated by a complex receptor system
[39]. Some studies suggest that it is the balance between
levels of IL-13Rα1 versus IL-13Rα2 that regulates the IL-
13 mediated response. Graham et al. [25] demonstrated
that vascular remodeling was reduced in mice with the loss
of IL-13Rα1 receptors, which leads to the loss of IL-13
function, in a non-significant manner. On the other hand,
mice without IL-13Rα2, and with an IL-13 gain-of-
function, presented thicker intimal layers in the pulmonary
vessels as well as higher right ventricular pressure. The
increased IL-13 signaling through the loss of IL-13Rα2
receptors was able to elicit PAH in this model. Other
authors have already reported that the imbalance in IL-13
receptors is the key feature for changing IL-13 signaling in
other animal models of PAH and in patients with idio-
pathic PAH, more than changes in circulating levels of this
cytokine [40,41]. Maybe, for this reason, the present study
failed to demonstrate increased serum levels of IL-13 in
patients with Sch-PAH. More recently, it was demon-
strated that increased levels of IL-4 and IL-13 mRNA and
proteins seen after exposure to S. mansoni, tended toward
suppression after blockage of the TGF-β signaling pathway.
These data suggest that IL-4/ IL-13 and TGF-β act mutu-
ally [27].
Although parasite eggs and S. mansoni-soluble egg anti-
gens were found in the lungs of experimentally infected
mice and in specimens of human intestine, there was no
significant amount of parasite-derived antigens within the
lungs of individuals who had died of Sch-PAH, despite the
presence of pulmonary vascular remodeling with plexi-
form lesions and arterial medial thickening [19]. This sug-
gests that after an initial acute inflammatory process,
which may be triggered when the schistosomula passes
through the lungs in genetically predisposed individuals,
vascular remodeling is established and can progress or
persist regardless of the presence of the antigen. Maybe
this process starts and progresses with the release of
cytokines and growth factors by the granulomas produced
in other sites, such as the liver.
Crosby et al. [42] demonstrated that treatment with
praziquantel was effective in eradicating adult worms of S.
mansoni, prevented PAH development and reversed pul-
monary vascular remodeling in infected mice. Contrary to
what occurs with liver fibrosis, which may reverse or
reduce with parasite treatment; this does not seem to
occur with the lung pathology of humans [19,43,44]. For
all these reasons it is important to clarify the immune
mechanisms involved in the pathogenesis of Sch-PAH, in
order to discover more effective therapy targets, acting
directly on the proliferative component of PAH.
Study limitations
The sample size in the present study was probably small,
but if we consider that this study enrolled individuals
with PAH of one single etiology, it was an important
sample of patients. TGF-beta1 and IL-13 were chosen
according to the new evidence encountered in studies
with animal models of Sch-PAH. This was a preliminary
study, therefore new studies using larger samples and
evaluating other growth factors and cytokines need to be
performed to confirm our results and bring new insights
into the immunopathogenesis of this devastating disease.
Conclusions
This study has demonstrated significantly increased serum
levels of TGF-beta1 in patients with Sch-PAH compared
with patients with schistosomiasis without PAH, suggest-
ing that this growth factor may contribute to vascular
remodeling in this disease. However, this study was not
able to detect a significantly elevated level of IL-13 in
patients with Sch-PAH, maybe because either a larger
sample size is necessary or an alteration in the IL-13
receptors is responsible for the augmented IL-13 signaling
found in animal models.
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